Unknown

Dataset Information

0

Stromal ColX?1 expression correlates with tumor-infiltrating lymphocytes and predicts adjuvant therapy outcome in ER-positive/HER2-positive breast cancer.


ABSTRACT:

Background

The breast cancer microenvironment contributes to tumor progression and response to chemotherapy. Previously, we reported that increased stromal Type X collagen ?1 (ColX?1) and low TILs correlated with poor pathologic response to neoadjuvant therapy in estrogen receptor and HER2-positive (ER+/HER2+) breast cancer. Here, we investigate the relationship of ColX?1 and long-term outcome of ER+/HER2+ breast cancer patients in an adjuvant setting.

Methods

A total of 164 cases with at least 5-year follow-up were included. Immunohistochemistry for ColX?1 was performed on whole tumor sections. Associations between ColX?1expression, clinical pathological features, and outcomes were analyzed.

Results

ColX?1 expression was directly proportional to the amount of tumor associated stroma (p?=?0.024) and inversely proportional to TILs. Increased ColX?1 was significantly associated with shorter disease free survival and overall survival by univariate analysis. In multivariate analysis, OS was lower in ColX?1 expressing (HR?=?2.1; 95% CI?=?1.2-3.9) tumors of older patients (>?=?58?years) (HR?=?5.3; 95% CI?=?1.7-17) with higher stage (HR?=?2.6; 95% CI?=?1.3-5.2). Similarly, DFS was lower in ColX?1 expressing (HR?=?1.8; 95% CI?=?1.6-5.7) tumors of older patients (HR?=?3.2; 95% CI?=?1.3-7.8) with higher stage (HR?=?2.7; 95% CI?=?1.6-5.7) and low TILs. In low PR+ tumors, higher ColX?1 expression was associated with poorer prognosis.

Conclusion

ColX?1 expression is associated with poor disease free survival and overall survival in ER+/HER2+ breast cancer. This study provides further support for the prognostic utility of ColX?1 as a breast cancer associated stromal factor that predicts response to chemotherapy.

SUBMITTER: Zhao CL 

PROVIDER: S-EPMC6825361 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Stromal ColXα1 expression correlates with tumor-infiltrating lymphocytes and predicts adjuvant therapy outcome in ER-positive/HER2-positive breast cancer.

Zhao Chaohui Lisa CL   Singh Kamaljeet K   Brodsky Alexander S AS   Lu Shaolei S   Graves Theresa A TA   Fenton Mary Anne MA   Yang Dongfang D   Sturtevant Ashlee A   Resnick Murray B MB   Wang Yihong Y  

BMC cancer 20191101 1


<h4>Background</h4>The breast cancer microenvironment contributes to tumor progression and response to chemotherapy. Previously, we reported that increased stromal Type X collagen α1 (ColXα1) and low TILs correlated with poor pathologic response to neoadjuvant therapy in estrogen receptor and HER2-positive (ER+/HER2+) breast cancer. Here, we investigate the relationship of ColXα1 and long-term outcome of ER+/HER2+ breast cancer patients in an adjuvant setting.<h4>Methods</h4>A total of 164 cases  ...[more]

Similar Datasets

| S-EPMC9564297 | biostudies-literature
| S-EPMC6695304 | biostudies-literature
| S-EPMC4713247 | biostudies-literature
| S-EPMC8197702 | biostudies-literature
| S-EPMC7766649 | biostudies-literature
| S-EPMC4835834 | biostudies-literature
| S-EPMC3899750 | biostudies-literature
| S-EPMC5880965 | biostudies-literature
| S-EPMC8902438 | biostudies-literature
| S-EPMC3446365 | biostudies-literature